Telix Pharmaceuticals Limited Deal History & Licensing Activity
Telix Pharmaceuticals Limited is a biotech headquartered in US. Over the past three years, Telix Pharmaceuticals Limited has been involved in 7 licensing and acquisition transactions, with a primary focus on Radiopharmaceuticals (8 deals). The company currently has 18 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
3
Active Trials
18
Top Modality
Radiopharmaceuticals
Focus Area
Solid Tumors
Telix Pharmaceuticals Limited Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Telix Pharmaceuticals Limited in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| ITM-11 (177Lu-edotreotide) | Telix | Radiopharmaceuticals | Phase 3 | acquisition | Sep 21, 2026 |
| Telix Pharmaceuticals radiopharma pact | Regeneron Pharmaceuticals, Inc. | Radiopharmaceuticals | Discovery | collaboration | Apr 13, 2026 |
Telix Pharmaceuticals Limited Pipeline Focus
Therapeutic areas and modalities where Telix Pharmaceuticals Limited is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Telix Pharmaceuticals Limited Clinical Pipeline
Telix Pharmaceuticals Limited has 18 active clinical trials across 3 development phases.
7
Phase 1
5
Phase 2
6
Phase 3
See How Your Asset Matches Telix Pharmaceuticals Limited's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Radiopharmaceuticals Benchmarks
Upfront, milestone, and royalty benchmarks for radiopharmaceuticals deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Telix Pharmaceuticals Limited Licensing & Deal Activity
Telix Pharmaceuticals Limited is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 7 deals over the past three years, Telix Pharmaceuticals Limited ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Telix Pharmaceuticals Limited include Solid Tumors (18 deals and trials), and Oncology (9 deals and trials). In terms of modality, Telix Pharmaceuticals Limited has shown particular interest in radiopharmaceuticals, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Telix Pharmaceuticals Limited and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Telix Pharmaceuticals Limited's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.